A large study of PIK3CA mutations in the community setting identifies varying degree of mutation positivity rates across age groups in advanced HR+, HER2-breast cancer patients using an FDA RT-PCR cleared test

被引：2

作者：

Chan, Alex C. ^{[1
]}

Weiss, Lawrence M. ^{[2
]}

Bender, Ryan ^{[1
]}

机构：

[1] Neogenomics, Carlsbad, CA USA

[2] Neogenomics, Aliso Viejo, CA USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

LAPATINIB;

D O I：

10.1158/1538-7445.SABCS19-P4-09-15

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-09-15

引用

页数：2

共 8 条

[1] A head-to-head comparison for detecting PIK3CA mutations in circulating tumor DNA of advanced HR+/HER2-breast cancer patients
Dandachi, N.
Graf, R.
Pancheri, L.
Dobric, N.
Klocker, E. V.
Suppan, C.
Jost, P. J.
Heitzer, E.
Balic, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1162 - S1163
[2] Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2-Breast Cancer
Venetis, Konstantinos
Pepe, Francesco
Munzone, Elisabetta
Sajjadi, Elham
Russo, Gianluca
Pisapia, Pasquale
Ivanova, Mariia
Bonizzi, Giuseppina
Vacirca, Davide
Rappa, Alessandra
Ranghiero, Alberto
Taormina, Sergio Vincenzo
Viale, Giuseppe
Troncone, Giancarlo
Barberis, Massimo
Guerini-Rocco, Elena
Malapelle, Umberto
Fusco, Nicola
CELLS, 2022, 11 (22)
[3] Testing HR+ / HER2-patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
Boutis, A.
Nikolaou, M.
Ardavanis, A.
Tolis, C.
Loga, K.
Korantzis, I.
Koumarianou, A.
Christopoulou, A. N.
Papatsimpas, G.
Bokas, A.
Pliarchopoulou, K.
Kampletsas, E.
Kesisis, G.
Biziota, E.
Psianou, K.
Karageorgopoulou, S.
Sogka, E. A.
Tsoukalas, N. G.
Chatzifoti, N.
Saridaki-Zoras, Z.
ANNALS OF ONCOLOGY, 2023, 34 : S366 - S366
[4] Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice at several Russian centers
Zhukova, Lyudmila
Filonenko, Daria
Grechukhina, Katerina
Stepanchencko, Margarita
Orlova, Rashida
Gluzman, Mark
Vakhitova, Almira
Goryainova, Alla
Fedyanin, Mikhail
Glazkova, Elena
Stroyakovsky, Daniil
Danilova, Anastasia
Pokataev, Ilya
Stativko, Olesia
Andreyashkina, Irina
Trotsenko, Ivan
Khatkov, Igor
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
Rajadurai, Pathmanathan
Semiglazova, Tatiana
Hegmane, Alinta
El Karak, Fadi
Chiu, Joanne W.
Gupta, Sudeep
Azim, Hamdy A.
Kitzen, Josef Jem
Arnaud, Antoine
Haftchenary, Sina
Wu, Jiwen
Menon-Singh, Lakshmi
Smith, LaTonya
Zhukova, Lyudmila
CANCER RESEARCH, 2022, 82 (04)
[6] Orthogonal assessment of PIK3CA and ESR1 mutation detection in longitudinal cfDNA samples from endocrine-resistant HR+/HER2-advanced breast cancer patients using dPCR and NGS-based SafeSEQ technology
Antras, Jesus Fuentes
Garcia-Barberan, Vanesa
Moreno, Fernando
Sloane, Hillary
Lopez-Cade, Igor
De Luna, Alicia
Pascual, Alejandro
Ramirez-Ruda, Carmen
Lorca, Victor
Flores, Paloma
Perez-Segura, Pedro
Ocana, Alberto
Preston, Jennifer
Quinn, Hannah
Jones, Frederick
Garcia-Saenz, Jose Angel
CANCER RESEARCH, 2022, 82 (04)
[7] A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2-breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Zhang, P.
Xu, B.
Sun, T.
Wang, Y.
Li, W.
Tong, Z.
Phadke, S.
Feinstein, T. M.
Qu, J.
Guo, P.
Ma, W.
Zhang, M.
Yue, Y.
ANNALS OF ONCOLOGY, 2024, 35 : S373 - S374
[8] Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC)
Jhaveri, Komal
Juric, Dejan
Varga, Andrea
Turner, Nicolas
Schmid, Peter
Saura, Cristina
Oliveira, Mafalda
Krop, Ian E.
Kalinsky, Kevin
Italiano, Antoine
Hamilton, Erika
Gambardella, Valentina
Cervantes, Andres
Bedard, Philippe L.
Liu, Bonnie P.
Chen, Jessica W.
Aimi, Junko
Royer-Joo, Stephanie
Schutzman, Jennifer L.
Hutchinson, Katherine E.
CANCER RESEARCH, 2021, 81 (04)

← 1 →